



GHC11USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/743,818 Confirmation No.: 8602
Applicant : Weiss et al
Filed : April 26, 2001
TC/A.U. : 1653
Examiner : Holly G. Schnizer
Customer No. : 00270
Title : PROTEASE SUSCEPTIBILITY II

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action on the merits. Therefore, a fee of \$180.00 is believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

06/15/2005 HTECKLU1 00000091 09743818

02 FC:1806 180.00 DP

Express Mail No. ED227898313US

REMARKS

The month of publication for documents (EEA), (EED), (EEE, and (EEF) could not be determined. The years of publication for this document is sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the document is not in issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08/B during the course of examination of this application.


Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By 
Cathy A. Rodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Phone: (215) 540-9200
Fax: (215) 540-5818

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number		09/743,818		
		Filing Date		April 26, 2001		
		First Named Inventor		Weiss et al		
		Group Art Unit		1653		
		Examiner Name				
Sheet	1	of	1	Attorney Docket Number		GHC11USA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	DDY	IMAI ET AL, Expression of Membrane-Type 1 Matrix Metalloproteinase and Activation of Progelatinase A in Human Osteoarthritic Cartilage, American Journal of Pathology, Vol. 151, No. 1, (July 1997)	
	DDZ	D'ORTHO ET AL, Membrane-Type Matrix Metalloproteinases 1 and 2 Exhibit Broad-Spectrum Proteolytic Capacities Comparable to Many Matrix Metalloproteinases, Eur. J. Biochem. 250, pp. 751-757 (September 1997)	
	EEA	BINI ET AL, Degradation of Cross-Linked Fibrin by Matrix Metalloproteinase 3 (Stromelysin 1): Hydrolysis of the γ Gly 404-Ala 405 Peptide Bond, Biochemistry, Vol. 35, No. 40, pp. 13056-13063 (1996)	
	EEB	SHIPLEY ET AL, The Structural Basis for the Elastolytic Activity of the 92-kDa and 72-kDa Gelatinases, Vol. 271, No. 8, pp. 4335-4341, (February 1996)	
	EEC	MECHAM ET AL, Elastin Degradation by Matrix Metalloproteinases, Vol. 272, No. 29, pp. 18071-18076, (July 1997)	
	EED	CHANDLER ET AL, Macrophage Metalloelastase Degrades Matrix and Myelin Proteins and Processes a Tumour Necrosis Factor- α Fusion Protein, Biochemical and Biophysical Research Communications, 228, pp. 421-429 (1996)	
	EEE	XIA ET AL, Comparison of Cleavage Site Specificity of Gelatinases A and B Using Collagenous Peptides, Biochimica et Biophysica Acta 1293, pp. 259-266, (1996)	
	EEF	YOUNG ET AL, Characterization of Gelatinases Linked to Extracellular Matrix Invasion in Ovarian Adenocarcinoma: Purification of Matrix Metalloproteinase 2, Article No. 0195, Gynecologic Oncology, 62, 89-99, (1996)	
	EEH	BELLÓN ET AL, Study of Biochemical Substrate and Role of Metalloproteinases in Fascia Transversalis from Hernial Processes, European Journal of Clinical Investigation, Vol. 27(6), pp. 510-516, (June 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**